Tempus AI Is a Buy, If You Can Handle the Volatility Tempus AI is well-positioned to capitalize on its extensive clinical data database. It can provide personalized treatment for hard-to-treat illness. MarketBeat · Feb 26, 2025
Conflicting Signals: Tempus AI's Stock Market Rally Tempus AI's stock has soared on completed acquisitions and product launches, yet mixed analyst sentiment signals a need for careful investor review. MarketBeat · Feb 17, 2025
Cathie Wood Just Doubled Down on This AI Stock. Should You? The stock is one of the renowned investor’s top holdings. Barchart · Jan 28, 2025
Tempus AI: A Game-Changer in AI-Powered Healthcare TEM surged 35% on Tuesday, fueled by the launch of its AI-powered health app Olivia and news of Nancy Pelosi's disclosed call option position in the stock. MarketBeat · Jan 22, 2025
Pelosi Sells 31K Apple and 10K Nvidia Shares, Eyes New AI and Utility Firm in a Major Portfolio Reshuffle Pelosi sold Apple and Nvidia shares while betting on Tempus AI and Vistra Corp. She also bought call options for both Amazon and Alphabet Class A stocks. International Business Times UK · Jan 21, 2025
1 AI Stock Cathie Wood Is Buying Instead of Tesla Cathie Wood is shifting away from Tesla, zeroing in on an AI-driven healthcare firm that is revolutionizing precision medicine and advanced diagnostics. Barchart · Dec 17, 2024
Should You Follow Cathie Wood Into This AI Diagnostics Stock? This AI diagnostics stock is a holding in Wood's ARKK and ARKG ETFs. Barchart · Aug 29, 2024